Taken together, these data suggest that the vast majority of PMMRDIA harbor genomic alterations leading to increased oncogenic RAS/PI3K/AKT signaling in addition to a combined inactivation of TP53 and RB1 tumor-suppressor pathways. This evidence concerns the gene TP53 and neoplasm.